News

Halozyme has posted net loss of $16.89m, compared to a net loss of $12.66m, for the same period in 2009. The company’s operating loss was $17.88m for the

Nectar Lifesciences is a research driven pharmaceutical organization, engaged in manufacturing and delivering pharmaceutical products. Nectar Lifesciences CEO and director said the Japanese audit is one of the

The company’s loss from operations was $14.45m for the full year ended 31 December 2010, compared to $78.94m for the same period in 2009. Affymax has generated net

In the first part, Biotron has dosed around 12 patients in the center, dddmag.com reported. Patients were divided according to the dosing of the drug, in which one-third

Emergent‘s income from operations was $34.96m for the fourth quarter of 2010, compared to $4.13m for the same period in 2009. The net income attributable to the company

Spencer Pharmaceutical said the patents are related to platform technologies for the efficient delivery of nucleic acids using chitosan as well as for an innovative discovery of therapeutic

Under this program, Jasco Pharma and NCCU are expected to combine the biological platform, tools and expertise at NCCU in the laboratory of Antonio Baines with Jasco Pharma’s

The multicentre, randomized, double-masked, sham injection-controlled, 36-month trial involved 377 patients with DME, who were randomised to receive monthly injections of either 0.3mg Lucentis (n=125), 0.5mg Lucentis (n=125)

The study results showed that adding aflibercept to the chemotherapy drug docetaxel did not meet the pre-specified criteria for primary endpoint, which was defined as improvement in overall